TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02974777
Drug: DAPT on-target
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard DAPT within the therapeutic window of platelet reactivity
Study: NCT02974777
Drug: DAPT intensification
Normalized name: DAPT
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of standard dose DAPT due to high platelet reactivity
Study: NCT05048498
Drug: NEX-18a injection
Normalized name: 17-ethynyl-17-hydroxy-18a-homoestr-4-en-3-one
DrugBank: Norgestrel (DB09389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection.
Study: NCT05048498
Drug: Azacitidine Injection
Normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
Study: NCT01204411
Drug: Artesunate-amodiaquine fixed-dose combination
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;~* artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;~* artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;
Study: NCT05822739
Drug: BBM-P002
Normalized name: BBMG
DrugBank: Bromothalonil (DB14199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
Study: NCT06186921
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.
Study: NCT04453059
Drug: Iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
Study: NCT00001005
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001005
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00236379
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target oral dose of 20 milligrams per day for 6 months
Study: NCT00236379
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target oral dose of 6 milligrams per day for for 6 months
Study: NCT05487196
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine belongs to the drug classification of antihypertensives
Study: NCT05487196
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine belongs to the drug classification of sedatives
Study: NCT05487196
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
Study: NCT05978206
Drug: Nandrolone Decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo
Study: NCT05096520
Drug: 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% lidocaine
Study: NCT05543707
Drug: PBI-0451 (Pomotrelvir)
Normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
Study: NCT06649331
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.
Study: NCT06649331
Drug: SHR-A1921
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.
Study: NCT06649331
Drug: SHR-A2009
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.
Study: NCT06649331
Drug: SHR-A2102
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
Study: NCT06378502
Drug: Amoxicillin Short
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short Span
Study: NCT05669014
Drug: Daxdilimab
Normalized name: Daxdilimab
DrugBank: Daxdilimab (DB16391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered daxdilimab by subcutaneous (SC) injection.
Study: NCT06378502
Drug: Amoxicillin Long
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long span
Study: NCT06728514
Drug: Inj Bupivacaine
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inj Bupivacaine 0.25% (10ml) in both groups
Study: NCT05400577
Drug: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Study: NCT05500677
Drug: Lidocaine topical
Normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
Study: NCT05083312
Drug: APT-1011
Normalized name: tetracycline
DrugBank: APT-101 (DB18003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
Study: NCT04804813
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib tablets
Study: NCT04808752
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
Study: NCT06214741
Drug: survodutide
Normalized name: Survodutide
DrugBank: Survodutide (DB18989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly subcutaneous injection
Study: NCT06138613
Drug: Tradipitant
Normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT03357419
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo oral capsule~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.
Study: NCT06398028
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green has a sharply defined spectral peak absorption of near-infrared light at 800 nm in blood plasma or blood. This is the same wavelength at which the optical density of oxygenated hemoglobin in blood approximately equals that of reduced hemoglobin. Therefore, this coincidental light absorption makes it possible to measure indocyanine green concentrations in blood, plasma and serum in terms of its optical density at 800 nm, independent of variations in oxygen saturation level
Study: NCT04453397
Drug: TNB-383B
Normalized name: TNB-383B
DrugBank: TNB-383B (DB17268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
Study: NCT03649438
Drug: 131 I-Metaiodobenzylguanidine
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~* Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~* Dose of \> 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available.
Study: NCT03649438
Drug: Potassium Iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
Study: NCT03649438
Drug: G-csf
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
Study: NCT05834582
Drug: Fluzoparib+Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
Study: NCT00000990
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04890522
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximum 6 cycles for combined therapy.
Study: NCT04890522
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maximum 6 cycles for combined therapy.
Study: NCT04890522
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maximum 6 cycles for combined therapy.
Study: NCT06077916
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo consisting of saline solution 250 mL is administered
Study: NCT00004442
Drug: ursodiol
Normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00681148
Drug: Botox injection
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intraprostatic injection of Botox (100 units for \< 30 cc prostate; 200 units for \> 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
Study: NCT00681148
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
Study: NCT05179070
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
Study: NCT05217667
Drug: ARO-ANG 3 Injection
Normalized name: ARO-APOC3
DrugBank: ARO-ANG3 (DB17626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
Study: NCT05510427
Drug: Infigratinib
Normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05510427
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by (IV) vein
Study: NCT05510427
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by (IV) vein
Study: NCT05704738
Drug: Rocatinlimab
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT04980027
Drug: Insulin glargine (U300)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
Study: NCT04199624
Drug: Omeprazole 20mg
Normalized name: OMEPRAZOLE 20MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole twice daily x 5 days
Study: NCT02142868
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
Study: NCT02142868
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
Study: NCT05623059
Drug: Slow Release DHEA
Normalized name: Slow-Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
Study: NCT04555785
Drug: Wilate
Normalized name: Wilate
DrugBank: Von Willebrand factor human (DB13133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
Study: NCT05844670
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial vincristine dosage will be according to institutional treatment protocol. After vincristine administration, three blood samples will be taken at T=1, T=1.5 and T=4 hours. The concentration of vincristine will be analyzed in the samples. If the concentration of 2 or more samples is lower than the reference concentration and there is no toxicity, an advice will be given to increase dosage by 20%. Whether or not a dosage is given, vincristine concentrations will be measured again for the next dose administration.~For the feasibility study, both venous blood samples and finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 2 times.~For the rest of the study, finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 3 times.~Toxicity will be monitored through physical exam and questionnaire, bilirubin levels and clinical status of the patient.
Study: NCT05915949
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Forxiga 10mg Tab once daily will be given to participants for 24 weeks.
Study: NCT05915949
Drug: Lobeglitazone 0.5 mg
DrugBank: Lobeglitazone (DB09198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
Study: NCT05915949
Drug: Dapagliflozin + Lobeglitazone
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
Study: NCT06107868
Drug: RP-6306
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.
Study: NCT06107868
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is an antineoplastic agent.
Study: NCT06107868
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is an antineoplastic agent.
Study: NCT05263674
Drug: Rapid sedation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
Study: NCT02699138
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg of trazodone to be administered orally once.
Study: NCT04940338
Drug: Dexamethasone Ophthalmic
Normalized name: dexAMETHasone ophthalmic
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery
Study: NCT00002214
Drug: Capravirine
Normalized name: Capravirine
DrugBank: Capravirine (DB08502)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00956176
Drug: Cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
Study: NCT05852704
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
Study: NCT06046105
Drug: Administering intraperitoneal bupivacaine for pain control after laparoscopic gynecological procedures
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr.
Study: NCT06046105
Drug: Administering intraperitoneal bupivacaine plus Dexmedetomidine for pain control after laparoscopic gynecological procedures
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Dexmedetomidine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr.
Study: NCT05132127
Drug: sutimlimab
Normalized name: Sutimlimab
DrugBank: Sutimlimab (DB14996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
Study: NCT04662060
Drug: Acebilustat
Normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule administered orally once daily
Study: NCT05630989
Drug: combination therapy with MEKi-HCQ
Normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Aminophenazone (DB01424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This cohort will receive combination therapy with MEKi-HCQ.
Study: NCT05630989
Drug: combination therapy with MEKi-EGFRi
Normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Aminophenazone (DB01424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This cohort will receive combination therapy with MEKi-EGFRi.
Study: NCT04812002
Drug: PD-1 inhibitor， bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both drugs are given intravenously
Study: NCT05298059
Drug: CPP-ACPF
Normalized name: CPPD
DrugBank: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine (DB14196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.